Giles Wilson Purchases 192 Shares of Dr. Martens (LON:DOCS) Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson purchased 192 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was bought at an average price of GBX 78 per share, with a total value of £149.76.

Giles Wilson also recently made the following trade(s):

• On Thursday, December 11th, Giles Wilson acquired 197 shares of Dr. Martens stock. The shares were bought at an average price of GBX 76 per share, for a total transaction of £149.72.
• On Tuesday, November 11th, Giles Wilson purchased 176 shares of Dr. Martens stock. The stock was purchased at an average price of GBX 85 per share, with a total value of £149.60.

Dr. Martens Price Performance

Shares of DOCS opened at GBX 75.70 on Friday. Dr. Martens plc has a 52 week low of GBX 43.02 and a 52 week high of GBX 100.87. The company has a current ratio of 2.85, a quick ratio of 1.13 and a debt-to-equity ratio of 127.27. The firm has a market cap of £731.69 million, a price-to-earnings ratio of 44.53, a PEG ratio of 6.40 and a beta of 0.11. The stock has a 50 day moving average of GBX 77.72 and a 200-day moving average of GBX 83.46.

Dr. Martens (LON:DOCS) last announced its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. As a group, analysts forecast that Dr. Martens plc will post 2.5809394 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on DOCS shares. Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a report on Thursday, November 20th. Berenberg Bank reissued a “buy” rating on shares of Dr. Martens in a research note on Thursday, November 27th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Dr. Martens has an average rating of “Moderate Buy” and an average price target of GBX 6,000.

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.